Skip Navigation LinksHome > July 2011 - Volume 27 - Issue 4 > Inflammatory bowel disease therapy: current state-of-the-art
Current Opinion in Gastroenterology:
doi: 10.1097/MOG.0b013e328347aef3
Inflammatory bowel disease: Edited by Claudio Fiocchi

Inflammatory bowel disease therapy: current state-of-the-art

Blonski, Wojciecha,b; Buchner, Anna Mb; Lichtenstein, Gary Rb

Collapse Box


Purpose of review: The aim of this article is to review current evidence-based approaches to treatment of ulcerative colitis and Crohn's disease.

Recent findings: The primary goal of treatment is to induce and to maintain remission in a safe and efficacious fashion. The 5-aminosalicylic acid (5-ASA) agents and oral steroids remain the first-line approach for the treatment of ulcerative colitis and Crohn's disease. The ‘step-up’ approach includes the use of immunomodulators [azathioprine (AZA), or 6-mercaptopurine (6-MP)] and newer biologic agents (infliximab, adalimumab, and natalizumab). The ‘step-down’ approach can also be considered individually on the basis of the severity of Crohn's disease.

Summary: Current treatment regimens still involve medications with well known efficacy and safety profiles and progress to more potent treatments such as immunomodulators and biologic agents. Adverse events of potent treatment with biologics and immunomodulators have been recognized. In some cases, aggressive approaches with the use of more potent agents as first-line therapy has been proposed, but they are still not considered a routine approach.

© 2011 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.